Plasma Levels of Tamoxifen, N-Desmethyl Tamoxifen and Anastrozole in a Patient with Metastatic Breast Cancer and Chronic Hemodialysis

Langenegger, Thomas; Wahl, Patricia; Schiesser, Daniela; Thürlimann, Beat

doi:10.1007/s10549-006-9243-7

Cited by 11 publications

(14 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…up to 15 ng/mL after oral application, clenbuterol up to 30 ng/mL, toremifene >1000 ng/mL, trenbolone 50 ng/mL (in horse plasma), exemestane up to 50 ng/mL, salbutamol 10 ng/mL after oral application, formoterol up to 20 ng/mL after inhalative administration (i.v. ), resveratrol 40 ng/mL and GW1516 in a range of 40 to 700 ng/mL 29–44. Plasma concentrations of over 5 µg/mL for the selected peptides were reported for growth hormone release peptide‐2 (GHRP‐2) after intravenous administration of 3 mg/kg (in rats) 45.…”

Section: Resultsmentioning

confidence: 99%

Comprehensive plasma‐screening for known and unknown substances in doping controls

Thomas

Guddat

Kohler

et al. 2010

Rapid Comm Mass Spectrometry

View full text Add to dashboard Cite

Occasionally, doping analysis has been recognized as a competitive challenge between cheating sportsmen and the analytical capabilities of testing laboratories. Both have made immense progress during the last decades, but obviously the athletes have the questionable benefit of frequently being able to switch to new, unknown and untested compounds to enhance their performance. Thus, as analytical counteraction and for effective drug testing, a complementary approach to classical targeted methods is required in order to implement a comprehensive screening procedure for known and unknown xenobiotics. The present study provides a new analytical strategy to circumvent the targeted character of classical doping controls without losing the required sensitivity and specificity. Using 50 microL of plasma only, the method potentially identifies illicit drugs in low ng/mL concentrations. Plasma provides the biological fluid with the circulating, unmodified xenobiotics; thus the identification of unknown compounds is facilitated. After a simple protein precipitation, liquid chromatographic separation and subsequent detection by means of high resolution/high accuracy orbitrap mass spectrometry, the procedure enables the determination of numerous compounds from different classes prohibited by the World Anti-Doping Agency (WADA). A new hyphenated mass spectrometry technology was employed without precursor ion selection for higher collision energy dissociation (HCD) fragmentation experiments. Thus the mass spectra contained all the desired information to identify unknown substances retrospectively. The method was validated for 32 selected model compounds for qualitative purposes considering the parameters specificity, selectivity, limit of detection (<0.1-10 ng/mL), precision (9-28%), robustness, linearity, ion suppression and recovery (80-112%). In addition to the identification of unknown compounds, the plasma samples were simultaneously screened for known prohibited targets.

show abstract

Section: Resultsmentioning

confidence: 99%

Comprehensive plasma‐screening for known and unknown substances in doping controls

Thomas

Guddat

Kohler

et al. 2010

Rapid Comm Mass Spectrometry

View full text Add to dashboard Cite

show abstract

“…There are no dialysis dose adjustments in the US prescribing information for trastuzumab. One study suggested that tamoxifen does not require dose adjustment in patients with CRF and breast cancer receiving regular dialysis 19. Tamoxifen is excreted by the intestine, is not filtered by the kidneys, and is not easily removed by dialysis treatment.…”

Section: Discussionmentioning

confidence: 99%

<p>Individualized Treatment Analysis Of Breast Cancer With Chronic Renal Failure</p>

Liu

Peng

Tang

2019

OTT

View full text Add to dashboard Cite

We report the case of a breast cancer patient with chronic renal failure (CRF). The clinical pharmacist adjusted the chemotherapy regimen and dosage according to the patient's renal function after reviewing the literature and analyzing the pharmacological and pharmacokinetic characteristics of the patient's antineoplastic drugs. To the best of our knowledge, this is the first report of successful multimodal treatment of breast cancer in a patient with CRF in China. The purpose of this case report is to optimize breast cancer therapy in patients with CRF and provide a reference for clinicians and clinical pharmacists to use antineoplastic drugs rationally.

show abstract

“…Orally administered tamoxifen has an almost 100% bioavailability [11]. e molecule has high lipophilicity, and more than 95% of the drug is transported bound to proteins.…”

Section: Hormone Therapymentioning

confidence: 99%

Limitations of Systemic Oncological Therapy in Breast Cancer Patients with Chronic Kidney Disease

Bednarek

Mykała-Cieśla

Pogoda

et al. 2020

Journal of Oncology

View full text Add to dashboard Cite

Breast cancer is the most common malignancy, affecting middle-age and older women frequently suffering from other chronic diseases, including chronic kidney disease. The risk of breast cancer development in women on renal replacement therapy (peritoneal dialysis and haemodialysis) is higher than in the general population. Chronic kidney disease does not limit surgical treatment or radiotherapy; however, it affects the pharmacokinetics of drugs used in the systematic treatment to a different extent, increasing their toxicity and the risk of adverse drug reactions. This article summarizes the current knowledge (published studies accessed through PUBMED) on drugs used in chemotherapy, hormone therapy, anti-HER2 drugs, CDK4/6 inhibitors, PARP inhibitors, and immune therapy in breast cancer patients undergoing dialysis. We discuss the data, the optimal choice of the chemotherapeutic protocol, and the administration of drugs in a specific time relation to the haemodialysis session to ensure the most effective and safe treatment to breast cancer patients.

show abstract

Plasma Levels of Tamoxifen, N-Desmethyl Tamoxifen and Anastrozole in a Patient with Metastatic Breast Cancer and Chronic Hemodialysis

Cited by 11 publications

References 12 publications

Comprehensive plasma‐screening for known and unknown substances in doping controls

Comprehensive plasma‐screening for known and unknown substances in doping controls

<p>Individualized Treatment Analysis Of Breast Cancer With Chronic Renal Failure</p>

Limitations of Systemic Oncological Therapy in Breast Cancer Patients with Chronic Kidney Disease

Contact Info

Product

Resources

About